Association of Cytomegalovirus DNA and Immunologic Markers of Cardiovascular Disease. by Garg, Ankita et al.
UC San Diego
UC San Diego Previously Published Works
Title
Association of Cytomegalovirus DNA and Immunologic Markers of Cardiovascular 
Disease.
Permalink
https://escholarship.org/uc/item/2x52s6pq
Journal
Open forum infectious diseases, 6(5)
ISSN
2328-8957
Authors
Garg, Ankita
Gianella, Sara
Nakazawa, Masato
et al.
Publication Date
2019-05-01
DOI
10.1093/ofid/ofz113
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
M A J O R  A R T I C L E
Subclinical CMV Replication and Immunologic Markers of Cardiovascular Disease • ofid • 1
Open Forum Infectious Diseases
 
Received 7 November 2018; editorial decision 27 February 2019; accepted 4 March 2019.
Correspondence: S. A. Spector, University of California, San Diego, 9500 Gilman Dr, La Jolla, 
CA 92093-0672 (saspector@ucsd.edu).
Open Forum Infectious Diseases®
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the 
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofz113
Association of Cytomegalovirus DNA and Immunologic 
Markers of Cardiovascular Disease
Ankita Garg,1 Sara Gianella,2 Masato Nakazawa,2 Rodney Trout,1 and Stephen A. Spector1,3
Departments of 1Pediatrics and 2Medicine, Division of Infectious Diseases, University of California, San Diego, La Jolla, and 3Rady Children’s Hospital, San Diego
Background. Persons living with human immunodeficiency virus (HIV) (PLWH) with high cytomegalovirus (CMV)–specific 
interferon (IFN) γ response have increased numbers of endothelium homing receptor (CX3CR1)+–expressing cells that are associ-
ated with cardiovascular disease. The current study was performed to investigate the effect of cellular levels of CMV DNA on these 
markers.
Methods. Eighty paired peripheral blood mononuclear cell samples were collected ≥12 months apart from 40 CMV-seropositive 
PLWH with suppressed HIV RNA, who started antiretroviral therapy at median of 3-months of infection. The samples were assessed 
for CMV-specific IFN-γ response by means of enzyme-linked immunospot assay, and participants were classified as low responders 
(LRs) or high responders (HRs) based on IFN-γ production (≤100 or >100 spot-forming units [SFUs]/105 cells).
Results. Of the 40 participants, 26 (65%) were HRs and 14 (35%) LRs at baseline, which did not change over time or by CMV 
levels (median at first/second time points, 383/308 SFUs/106 cells for HRs vs 21/41 SFUs/106 for LRs). A decrease in IFN-γ over time 
was associated with higher CMV DNA levels (P < .01). High CMV response was also associated with increased CD28+CD27−CD4+ 
T cells expressing CX3CR1 (P  <  .001). Similarly, increased IFN-γ production was associated with increased CMV-specific 
CX3CR1+CD28+CD27−CD4+ and CD8+ T cells (P < .001).
Conclusions. These findings demonstrate that levels of CMV-specific IFN-γ response in PLWH are stable over time, and that 
HRs have increased circulating T cells expressing CX3CR1 that may put them at increased risk of cardiovascular disease and other 
inflammatory diseases.
Keywords. cardiovascular disease; CX3CR1 memory cells; people living with HIV; sub clinical CMV.
Human cytomegalovirus (CMV) establishes a latent infection 
that can periodically reactivate without overt clinical disease 
in the immunologically normal host [1, 2]. In immunocom-
promised individuals including transplant recipients, and per-
sons living with human immunodeficiency virus (HIV) type 1 
(PLWH), reactivation of CMV frequently can result in severe 
disease. Even in coinfected PLWH with preserved immune sys-
tems taking antiretroviral therapy (ART), reactivation of CMV 
is common, but CMV disease rarely occurs [2–4].
Increasingly, the immune response against CMV is being 
recognized as a potential cause of acute and chronic inflam-
mation [5–8]. For PLWH starting ART, the restoration of im-
munity associated with an increase in CD4+ cells can result in 
an acute immune reconstitution inflammatory syndrome that 
is usually directed against opportunistic organisms, including 
CMV [9–12]. Numerous studies have shown that CMV-specific 
cellular immunity mediated by cytokine CD4+ and cytolytic 
CD8+ T cells is crucial for the control of CMV replication [7, 
13–15]. T-helper 1 cytokines, interferon (IFN) γ and tumor 
necrosis factor (TNF) α, are produced by CMV-specific CD4+ 
T cells before CMV-specific antibodies and cytolytic CD8+ T 
cells [13–16]. Paradoxically, although these cytokines are cen-
tral to an effective immune response, persistent expression of 
IFN-γ by CMV-specific effector T cells can result in chronic 
inflammation and immune activation contributing to immune 
senescence and cardiovascular complications [17–21]. Thus, 
CMV-specific CD4+ T cells are regulators of protective immu-
nity and immunopathology, in particular related to cardiovas-
cular disease (CVD) [22, 23].
Endothelial cell inflammation and damage play a critical 
role in the development of CVD and atherosclerosis [24–26]. 
Atherosclerosis is considered a nonresolving inflammatory dis-
ease characterized by migration and infiltration of activated 
macrophages and T cells within the atherosclerotic lesions 
and is mediated by the CX3CL1 (fractalkine)–CX3CR1 axis 
[17, 18, 27–29]. Both human studies and animal models sug-
gest that CMV infection contributes to chronic endothelial cell 
inflammation and vascular damage [17, 18, 20, 21, 30, 31]. In 
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the setting of HIV infection, coinfection with CMV could po-
tentiate the inflammatory process by expanding the number of 
CMV-specific CX3CR1+ T cells, with the release of IFN-γ and 
TNF-α leading to the increased expression of CX3CL1 on en-
dothelial cells [17, 18, 20]. In turn, this increase promotes the 
migration of CX3CR1 inflammatory cells to the arterial wall, 
resulting in chronic inflammation and atherosclerosis. Previous 
studies have shown that (1) CD4+ T cells in the immunocom-
petent host with prior CMV infection respond to CMV antigen 
presented by endothelial cells and produce IFN-γ and TNF-α 
and (2) individuals with high frequencies of CMV-specific T 
cells have higher levels of CX3CL1 and endothelial cell damage 
than those with low frequencies [17, 18].
In the current study, we hypothesized that if CMV increases 
the risk of CVD in PLWH, a subset of individuals can be 
identified who maintain persistently high levels of IFN-γ–
producing CMV-specific CX3CR1-bearing T cells over time. 
We also posited that increased levels of CMV DNA detected 
over time would be associated with those individuals identified 
as having specifically high proportions.
MATERIALS AND METHODS
Study Participants
Paired peripheral blood mononuclear cell (PBMC) samples 
from 40 men who have sex with men were obtained from a re-
pository of samples collected longitudinally from the San Diego 
Primary Infection Resource Consortium between November 
2001 and January 2013. All participants were CMV and Epstein-
Barr virus (EBV) seropositive. The estimated date of HIV infec-
tion was calculated using established algorithms [32]. ART was 
initiated a median of 3 months after this date. In all participants, 
complete suppression of HIV RNA had been achieved by the 
time of the first sample, a median of 34 weeks after ART initi-
ation; a second sample was obtained ≥12 months after the first 
specimen tested. This study was approved by the University of 
California, San Diego, Office of Human Research Protections 
Program.
CMV and EBV DNA Quantification
CMV and EBV DNA levels were quantified in 5 × 106 PBMCs 
by means of digital droplet polymerase chain reaction, as 
described elsewhere [33]. Copy numbers were calculated as the 
mean of replicate polymerase chain reaction measurements and 
normalized to 1 × 106 cells, as determined by ribonuclease P/
MRP subunit p30.
Cell Isolation and Culture
Cryopreserved PBMCs were centrifuged, washed, resuspended 
in R10 media, and incubated overnight at 37oC and 5% carbon 
dioxide. On day 2, cells were washed with R10 media, assessed 
for viability using the trypan blue exclusion method, and cul-
tured in Roswell Park Memorial Institute 1640 medium (Gibco) 
and 10% human serum (MP Biomedicals) in the presence or 
absence of the immunodominant tegument pp65 peptide pool 
of CMV (2 µg/mL) (National Institutes of Health AIDS reagent 
program).
IFN-γ Enzyme-Linked Immunospot Assay
Frequencies of IFN-γ–producing cells were determined by 
means of enzyme-linked immunospot (ELISPOT) assay. PBMCs 
were thawed and rested overnight, and 105 viable cells were cul-
tured in ELISPOT plates coated with capture antibody for IFN-γ 
(BD Biosciences), with or without pp65 peptide pool (2 µg/mL). 
Cytokine-producing cells were detected using kits for IFN-γ 
(BD Biosciences), according to the manufacturer’s instructions. 
Spot-forming units (SFUs) were automatically calculated with 
ImmunoSpot software for pp65 peptide pool stimulation and 
medium-only (negative) control wells. Data are presented as 
mean IFN-γ response in SFUs per 105 cells produced by pp65, 
minus vehicle control. Participants producing IFN-γ at ≤100 or 
>100 SFUs/105 cells were classified as low responders (LRs) or 
high responders (HRs), respectively.
Antibodies and Other Reagents
The following antibodies were used for flow cytometry: Alexa 
Fluor488-anti-CD45RA, phycoerythrin (PE)–anti-CD57, 
allophycocyanin/cyanine 7 (Cy7) or PE/Cy7–anti-CD3, Alexa 
Fluor 647–anti-CX3CR1, Alexa Fluor 700–anti-CD27, Brilliant 
Violet 510–anti-CD28, PE/Cy7–anti-CD8 and Brilliant Violet 
650–anti-CD279 (programmed cell death protein-1-PD-1) (all 
from Biolegend); LIVE/DEAD fixable violet dye (Molecular 
Probes); allophycocyanin–eFluor 780–anti-CD4 (both from 
ebiosciences)
Immunolabeling and Flow Cytometry
Cells were surface stained for surface markers using respective 
antibodies and cell staining buffer (Biolegend). Flow cytometry 
was performed using a FACS Canto cytometer, and live cells 
were analyzed using FlowJo software (Tree Star). Controls for 
each experiment included unstained cells control, fluorescence-
minus-one controls, and isotype-matched antibodies.
Statistical Analysis
Nonparametric tests were first used to determine associations 
between 2 variables. IFN-γ production was compared between 
LRs and HRs with nonparametric Mann-Whitney U test and 
between the 2 time points with Wilcoxon matched-pairs test; 
comparisons between different parameters were analyzed 
using Spearman correlation. Subsequently, we developed linear 
mixed-effects regression models to investigate the relationship 
of CMV shedding to each of the following outcomes during ART: 
(1) IFN-γ production; (2) CX3CR1-expressing CD45RA−CD4+ 
T cells; (3) CX3CR1-expressing CD45RA−CD8+ T cells; (4) 
CX3CR1 expressed on CMV-specific CD45RA−CD4+ T cells; 
(5) CX3CR1 expressed on CMV-specific CD45RA−CD8+ T cells; 
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and (6) PD-1 expression on circulating CD45RA−CD28+CD27− 
effector memory T (TEM) cells. 
Because the CMV and EBV data were not collected at the same 
time as the immunologic data, we estimated mean levels of 
CMV and EBV shedding for each individual with Bayesian hi-
erarchical models using ≥2 DNA measurements from each par-
ticipant to estimate the CMV and EBV DNA levels, as described 
elsewhere [33]. In all models, we tested the association of the fol-
lowing fixed effects with the outcome: (1) time (between visits 
1 and 2 in weeks); (2) estimated CMV level; (3) estimated EBV 
level; and (4) IFN-γ level (when that was not the outcome). In the 
models of CX3CR1+, we added the cell subtype (CD28−CD27−, 
CD28+CD27−, CD28−CD27+, and CD28+CD27+) as a fixed and 
random effect. We tested the interactions of all fixed effects with 
time and cell subtype. Effects associated with the outcome at the 
10% significance level were considered for the final models.
RESULTS
Participants, Clinical Characteristics, and HIV and CMV Status
Eighty blood samples were collected longitudinally from 40 
recently HIV-infected participants who were CMV and EBV 
seropositive. All participants had achieved complete suppres-
sion of HIV RNA (defined as <50 copies/mL) with ART during 
study follow-up and had 2 stored PBMC specimens obtained 
≥1 year apart. Clinical and demographic data are summarized 
in Table 1.
Response to CMV over time
Previous studies showed that the host CD4+ T-cell response to 
CMV antigen can produce IFN-γ and TNF-α at levels sufficient 
to drive the induction of endothelial cell CX3CL1 (fractalkine), 
a key marker of endothelial cell inflammation [17, 18]. It has 
also been demonstrated that, according to their IFN-γ re-
sponse, CMV-seropositive persons can be divided into HRs and 
LRs [18]. In the current study, we tested the hypothesis that re-
sponse to CMV in HIV/CMV-coinfected individuals with sus-
tained HIV suppression would remain constant over time (ie, 
that HRs would remain HRs and LRs would remain LRs).
Initially, we quantified the response to CMVpp65 by using 
ELISPOT to determine the frequency of cells producing IFN-
γ. Of the 40 study participants, 26 (65%) were HRs (mean 
IFN-γ response [standard deviation (SD)], 416.2  [41.7] 
SFUs/105 cells) and 14 (35%) were LRs (43.9  [10], SFUs/105 
cells) (Figure 1A). Next, we evaluated the change in IFN-γ in 
response to CMVpp65 ≥12 months after the first time point. 
Although the response to CMVpp65 at the second time point 
declined in HRs (mean [SD] IFN-γ response, 388.5  [42] vs 
310 [38] SFUs/105; P = .007), it did not change significantly in 
LRs (36 [10] vs 41 [30]; P = .23), and each group of responders, 
with few exceptions, maintained their response category 
(Figure 1B and 1C).
CMV DNA Load and CMV-Specific IFN-γ Response
Our next series of analyses was designed to determined whether 
the CMV load as measured by CMV DNA in peripheral blood 
cells altered the IFN-γ response. Because 10 (25%) of the 40 
participants had CMV DNA measured on the same date as the 
outcome measures, we used ≥2 CMV DNA measurements from 
different dates and applied Bayesian hierarchical modeling [33] 
to all CMV DNA measurements to calculate an estimate of CMV 
DNA shedding for each person. Interestingly, the amount of 
CMV DNA was not associated with the magnitude of IFN-γ re-
sponse at baseline (P > .20). However, the change in IFN-γ levels 
over time was influenced by CMV DNA levels (CMV × time in-
teraction, −1.85 [0.67]; P < .01). Specifically, a more rapid decline 
in IFN-γ levels over time was associated with higher amounts of 
CMV DNA (ie, above the average estimated CMV DNA level). 
To visualize this association, we computed the change in IFN-γ 
levels from visit 1 to visit 2 and plotted it against estimated CMV 
DNA levels (Figure 2). As the significant CMV-time interac-
tion indicates, lower expected CMV DNA levels were associated 
with increases in IFN-γ over time, and higher CMV levels with 
decreases in IFN-γ. For instance, expected CMV DNA levels of 
1.6 and 3.1 copies/µL (ie, 1 SD below and above the mean) were 
associated with an IFN-γ increase by 46.6 SFUs/105 (95% con-
fidence interval, −40.1 to 133.3) and a decrease by 108.5 points 
(17.0–200.1) from visit 1 to visit 2, respectively. This CMV-time 
interaction was significant even after outliers were removed or 
the outcome was log-transformed (P < .05).
Table 1. Demographic and Clinical Variables in Study Participants 
(N = 40)
Variable Median Value (IQR)a
Male sex, no. (%) 40 (100)
Age, y 35.00 (26.50–39.50)
EDI to ART, mo 3.00 (2.50–8.50)
Baseline values  
 Log viral load, log10 copies/ml 11.34 (10.37–13.30)
 CD4+ cell count, cells/μl 485.50 (362.25–649.50)
 CD4+/CD8+ T-cell ratio, copies/µL 0.47 (0.32–0.60)
CMV DNA copies  
 Time 1 5.19 (2.80–9.58)
 Time 2 3.21 (0.00–5.38)
EBV DNA, copies/μL  
 Time 1 83.15 (20.67–247.45)
 Time 2 12.10 (2.14–68.59)
Circulating CD4+CX3CR1+ cells, %b  
 Time 1 0.60 (0.38–1.06)
 Time 2 0.66 (0.43–1.06)
Circulating CD8+CX3CR1+ cells, %b  
 Time 1 0.61 (0.35–1.22)
 Time 2 0.81 (0.30–1.27)
Abbreviations: ART, antiretroviral therapy; CMV, cytomegalovirus; EBV, Epstein-Barr virus; 
EDI, estimated date of infection; IQR, interquartile range.
aData represent median (IQR) values unless otherwise specified. 
bCirculating CD4+CX3CR1+ and CD8+CX3CR1+ cell values represent means across 
subtypes. 
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EBV DNA Load and CMV IFN-γ Response
To assess whether the change in the IFN-γ response to CMV 
was specific to the estimated CMV DNA load, we examined the 
association between CMV IFN-γ and the estimated EBV DNA 
load. We selected EBV to study because it is 100% prevalent 
among the study cohort and is a herpesvirus that is frequently 
reactivated in immunosuppressed individuals, including those 
infected with HIV. Using the same method as for CMV, we 
found no association between the CMV IFN-γ response and 
EBV (P > .2).
Association of CMV With CX3CR1+ Memory CD4+ and CD8+ T Cells
HIV/CMV-coinfected individuals are potentially at increased 
risk of atherosclerosis, and CMV-specific CX3CR1-bearing 
CD4+ T cells can promote chronic inflammation [20, 21]. 
Therefore, we hypothesized that HIV/CMV-coinfected 
individuals with a high response to CMV would have a higher 
frequency of memory CD4+CX3CR1+ T cells. To examine this 
relationship, we determined the correlation between the fre-
quency of IFN-γ–producing cells (in SFUs per 105 cells) in re-
sponse to CMVpp65 and circulating CD45RA−CD4+CX3CR1+ 
memory T cells in the 2 samples obtained ≥12 months apart. 
The IFN-γ response was strongly correlated with CD4+ 
count at baseline (r  =  0.811; P  <  .001), and this relationship 
persisted over time (r  =  0.4; P  =  .01) (Figure 3A, left and 
right). Similarly, IFN-γ was correlated with the frequency of 
CD45RA−CD8+CX3CR1+ memory T cells at baseline (r = 0.4; 
P = .01), but this was no longer significant over time (r = 0.25; 
P = .12) (Figure 3B, left and right).
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Figure 2. Estimated cytomegalovirus (CMV) DNA levels are inversely correlated 
with the change in interferon (IFN) γ over time. Peripheral blood mononuclear cells 
from human immunodeficiency virus–infected, CMV-infected individuals (n  =  40) 
were collected at 2 time points >12 months apart (times 1 and 2), and the frequency 
of cells producing IFN-γ (in spot-forming units [SFUs] per 105 cells) in response to 
CMVpp65 was determined by means of enzyme-linked immunospot assay, as in 
Figure 1. Black dots represent change in IFN-γ from visit 1 to visit 2; black line and 
shaded area, model-estimated values and their 95% confidence intervals. *P < .01.
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Figure 1. Change in interferon (IFN) γ over time. A, Peripheral blood mononu-
clear cell (PBMCs) from 40 men coinfected with human immunodeficiency virus 
and cytomegalovirus (CMV) were collected at 2 time points (times 1 and 2), the 
first sample a median of 34 weeks after the start of antiretroviral therapy (A) 
and the second >12 months later (B, C). PBMCs were cultured on enzyme-linked 
immunospot (ELISPOT) plates coated with capture anti–IFN-γ antibody, with or 
without CMVpp65 (2 µg/mL). After 18 hours, plates were washed, and biotinylated 
anti-IFN-γ detection antibody was added for 2 hours, followed by the addition of 
streptavidin–horseradish peroxidase enzyme conjugate for 1 hour; plates were then 
washed, and substrate was added using the AEC substrate kit (BD Biosciences). The 
substrate reaction was stopped by washing wells with water. Spots were air dried, 
and counted with an automated ELISPOT reader, which calculated the number of 
spot-forming units (SFUs) per 105 PBMCs. Participants producing IFN-γ at >100 or 
≤100 SFUs/105 cells were classified as high responders (HRs) (B) or low responders 
(LRs) (C), respectively. For all graphs, each dot represents an individual donor, plots 
include observations from the 25th to 75th percentiles, and horizontal lines repre-
sent median values. *P = .27; **P < .005; ****P < .001.
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CD4+CX3CR1+ T Cells Consist of CD28+CD27− Memory Subsets in HIV/CMV-
Coinfected Individuals
Because TEM cells have the ability to produce effector cytokines, 
IFN-γ and TNF-α, and our findings showed that IFN-γ is asso-
ciated with circulating frequency of CD45RA−CD4+CX3CR1+ 
cells (Figure 3A), we next determined the frequency of the 
TEM cell subset in the CD45RA
−CD4+CX3CR1+ memory 
cell population. Initially, we measured the relationship be-
tween the estimated CMV DNA level and CD28+CD27+, 
CD28−CD27+, CD28+CD27−, and CD28−CD27− subsets in 
CD45RA−CD4+CX3CR1+ memory cells present in PBMCs of 
HIV/CMV-coinfected participants. 
After the significant IFN-γ by subset interaction effects were 
controlled for (P < .001), CMV was negatively associated with 
the CD28−CD27− subset (−12.3 [4.4]; P < .01) and positively as-
sociated with the CD28+CD27− subset (11.7 [4.4]; P < .01) but 
not with CD28+CD27+ (2.8 [4.4]; P = .56) or CD28−CD27+ (−2.3 
[4.4]; P = .60; Figure 4A). Unlike with CD45RA−CD4+CX3CR1+ 
T cells, the relationship between CD45RA−CD8+CX3CR1+ and 
the estimated CMV DNA levels was neither significant (P > .2) 
nor dependent on T-cell subsets (P > .2), even though it was as-
sociated with IFN-γ in the CD28+CD27+ subset (−21.8 [11.0]; 
P  <  .05). Neither outcome was associated with time or EBV, 
with or without interacting with other variables (P > .2). These 
findings suggest that CMV shedders have a higher frequency of 
circulating CD4+ TEM cells that coexpress CX3CR1.
Next, we evaluated whether the expansion of TEM cells de-
fined by CD27 and CD28 is specific to CMV antigen. PBMCs 
were cultured with or without a CMVpp65 peptide pool; the 
frequency of memory subsets was determined by means of flow 
cytometry. The frequency of IFN-γ–producing cells (in SFUs per 
105 cells) significantly changed over time (P = .02) and was as-
sociated with CMV-specific CD45RA−CD4+CX3CR1+ levels in 
a subtype-dependent manner (P < .001). Specifically, this asso-
ciation was significantly positive with the CD28+CD27− subset 
(13.4  [3.6]; P  <  .01) (Figure 4B) but not with CD28+CD27+ 
(−3.0  [3.6]; P  =  .40), CD28−CD27+ (−0.9  [3.6]; P  =  .91), or 
CD28−CD27− (−4.7  [3.6]; P =  .38). This outcome was not as-
sociated with EBV with or without interaction with subsets 
(P >  .2). CMV-specific CD45RA−CD8+CX3CR1+ levels were 
8A A
B B
C
ir
cu
la
tin
g 
C
D
4+
C
X
3C
R
1+
 C
el
ls,
 % 6
4
2
0
C
ir
cu
la
tin
g 
C
D
8+
C
X
3C
R
1+
 C
el
ls,
 %
0
1
2
3
4
C
ir
cu
la
tin
g 
C
D
8+
C
X
3C
R
1+
 C
el
ls,
 %
0
1
2
3
4
8
0 200 400 600 800
IFN-γ (SFUs/105 Cells)
0 200 400 600 800
IFN-γ (SFUs/105 Cells)
0 200 400 600 800
IFN-γ (SFUs/105 Cells)
0 200 400 600 800
IFN-γ (SFUs/105 Cells)
C
ir
cu
la
tin
g 
C
D
4+
C
X
3C
R
1+
 C
el
ls,
 % 6
r= 0.811
P< .001
r= 0.400
P= .01
r= 0.400
P= .01
r= 0.250
P= .12
4
2
0
(i) (ii)
(i) (ii)
Figure 3. Association of cytomegalovirus (CMV) with CX3CR1+ memory CD4+ and CD8+ T cells. To determine whether the interferon (IFN) γ response to CMV correlates with 
the frequency of circulating CD45RA−CX3CR1+ CD4+ and CD8+ memory cells (CD4+CX3CR1+ and CD8+CX3CR1+ cells), peripheral blood mononuclear cells of donors coinfected 
with CMV and human immunodeficiency virus were stained with antibodies against CD14, CD3, CD4, CD8, CD45RA, and CX3CR1 and LIVE/DEAD fixable violet dye, and live 
cells were analyzed as CD14−CD3+ CD45RA−CX3CR1+ CD4+/CD8+by means of flow cytometry. A, Percentages of CD4+CX3CR1+ cells were determined and correlations be-
tween the percentage of CD4+CX3CR1+ cells and the frequency of IFN-γ–producing cells at times 1 (left) and 2 (right) were calculated. B, Percentages of CD8+CX3CR1+ cells 
were determined and correlations between the percentage of CD8+CX3CR1+ cells and the frequency of IFN-γ–producing cells at times 1 (left) and 2 (right) were calculated. 
For all graphs, each dot represents an individual donor. 
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associated with IFN-γ in the CD28+CD27− subtype (28.8 [5.6]; 
P < .001), but not with any other factors (P > .2). Collectively, 
these findings indicate that HIV/CMV-coinfected persons with 
suppressed HIV RNA have a high frequency of CMV-specific 
CD28+CD27− memory T cells that coexpress CX3CR1 and 
IFN-γ.
In an earlier study, we showed that men who have sex with 
men and who are living with HIV and have detectable CMV 
in their semen had higher levels of PD-1 expression on cir-
culating CD45RA−CD28+CD27− TEM cells than those without 
detectable genital CMV DNA [34]. Therefore, we sought to as-
sess whether PD-1 expression is associated with CMV-specific 
CD45RA−CD4+CX3CR1+ memory T cells in PLWH with detect-
able CMV DNA in blood cells. For these studies, PBMCs were 
cultured with or without CMVpp65, and the mean fluorescence 
intensity of PD-1 was determined on CD45RA−CD4+CX3CR1+ 
cells using flow cytometry (mean [SD], 416.7  [76]; median, 
142.5) (Figure 5A). 
We identified a subset of PLWH with very low to unde-
tectable levels of PD-1 expression. However, these individuals 
were still capable of producing IFN-γ, as determined by CMV 
ELISPOT (mean [SD] IFN-γ response, 238.5 [34.24] SFUs/105 
cells; median, 174 SFUs/105 cells) (Figure 5B). Overall, PD-1 
expression on CD4+ T cells was associated with IFN-γ expres-
sion (626.3 [254.3]; P =  .02) (Figure 5C) and time (P =  .04) 
but was not associated with CMV DNA level, with or without 
interaction with time (P >  .2). PD-1 expression on CD4+ T 
cells was not associated with CMV DNA in CD4+CX3CR1+ 
T-cell subsets (P  >  .2). PD-1 expression on CD8+ T cells 
was associated with IFN-γ expression (1035  [331]; P  <  .01) 
(Figure 5D) but not with any other factors (P > .2). Thus, we 
identified a subset of HIV-CMV-coinfected individuals with 
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Figure 4. CD4+CX3CR1+ T cells consist of CD28+CD27− memory subsets in individuals coinfected with human immunodeficiency virus and cytomegalovirus (CMV). Peripheral 
blood mononuclear cells (PBMCs) from such coinfected donors (n = 40) taking antiretroviral therapy (ART) were at >12 months apart (first sample obtained a median of 34 
weeks after ART initiation). PBMCs from both time points (n = 80) were either stained (A) or first cultured (B) with or without CMVpp65 (2 µg/mL) for 48 hours and then stained 
with antibodies against CD14, CD3, CD4, CD45RA, CX3CR1, CD27, and CD28 and LIVE/DEAD fixable stain. Live cells were analyzed as CD14−CD3+CD4+CD45RA−CX3CR1+, 
and percentages of CD28−CD27−, CD28−CD27+, CD28+CD27−, and CD28+CD27+ cells were determined using flow cytometry. A, Circulating frequency of T-cell subsets were 
analyzed with estimated CMV DNA levels. B, CMV-specific T-cell subsets were analyzed with the frequency of cells producing interferon (IFN) γ. Gray dots represent the 
means of measures from visits 1 and 2; black lines, regression lines; and gray shading, 95% confidence intervals. Regression (β) coefficient with standard error. *P < .01.
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a memory T-cell phenotype of CD4+CX3CR1+PD-1− that 
produces IFN-γ.
DISCUSSION
Since the 1970s, the role of microbial organisms in CVD has been 
intensely investigated. In particular, CMV has been implicated 
as a risk factor for atherosclerosis in many epidemiologic, clin-
ical, animal, and in vitro studies [30, 31, 35–37]. To promote the 
atherogenic process, a pathogen must be able to infect endothe-
lial cells, establish persistent infection, and elicit a robust im-
munologic response that can persist over decades. Moreover, to 
have a broad effect on a population basis, the pathogen should 
infect a large proportion of persons. Thus, although other 
pathogens may demonstrate some of these properties, CMV, 
more than any other infectious agent, meets all of these criteria 
in HIV-uninfected and HIV-infected populations. Consistent 
with observations in HIV-uninfected individuals and trans-
plant recipients, CMV has constantly emerged in PLWH as the 
most common pathogen associated with early signs of cardiac 
disease [20, 38]. However, because most of the human studies 
associating CMV humoral and cell-mediated responses have 
been cross-sectional, few longitudinal data exist indicating that 
a subgroup of persons can be identified as being at increased 
risk for CVD based on their immunologic response to CMV. 
This information is of particular importance in PLWH, almost 
100% of whom are coinfected with CMV.
Previous studies have shown that CMV-seropositive HIV-
uninfected individuals with high frequencies of CMV-specific T 
cells, when compared with donors with low levels of such cells, 
have higher quantities of CX3CL1 in endothelial cells, which 
is associated with damage and loss of endothelial cells [18, 
39]. In the current study, we show that HIV/CMV-coinfected 
individuals with high CMV frequencies maintain their response 
status irrespective of levels of detectable CMV DNA over time. 
Thus, they are potentially at increased risk of CMV-associated 
inflammatory conditions, including CVD.
CX3CR1 is the receptor for chemokine CX3CL1 and also 
serves as the homing receptor expressed on memory T cells 
[40–42]. The CX3CR1-CX3CL1 axis has emerged as a key reg-
ulator of inflammation and vascular injury [20, 27, 29]. In HIV-
uninfected individuals, CX3CL1 is up-regulated on endothelial 
cells in response to CMV antigen stimulation of PBMCs from 
CMV-seropositive individuals, and this response is markedly 
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increased in persons with a high frequency of CMV [17, 18]. 
Moreover, CX3CR1-bearing cells have been identified as the 
major IFN-γ–producing cells, and cells expressing CX3CR1, 
including T cells, macrophages and natural killer cells, are the 
major cell type recruited to endothelial sites of inflammation 
[39, 43]. Our current data confirm and expand on these findings, 
and they demonstrate that the increased number of CX3CR1-
bearing cells is significantly correlated with CMV-specific 
IFN-γ production. The link to CVD is further supported by 
the induction of CX3CL1 production in endothelial cells when 
exposed to TNF-α and IFN-γ, and in HIV/CMV-coinfected 
individuals, there is a positive correlation between circulating 
CD4+CX3CR1+ T cells and intima-media thickness [20].
The data presented here further establish that the fre-
quency of cells producing IFN-γ in response to CMVpp65 
is directly correlated with the frequency of circulating 
CD45RA−CD4+CX3CR1+ memory T cells in HIV-CMV-
coinfected individuals. Importantly, this correlation is 
maintained after prolonged HIV suppression with ART. During 
chronic CMV infection, repeated antigenic stimulation causes 
memory CD8+ T cells to accumulate at high frequencies, 
reaching up to 20% of total CD8+ T cells, called “inflated 
memory” CD8+ T cells [44–47]. Earlier studies have established 
that memory CD4+ T cells specific for CMV glycoprotein B 
and pp65 can also expand, reaching frequencies comparable to 
those of CD8+ T cells [48]. Of interest, CD8+ T-cell inflation 
during latent murine CMV infection is strongly dependent on 
CD4+ T-cell helper function [49]. Our findings that individuals 
with a high frequency of CMV maintain their response status 
suggests that those with high CMV frequencies undergo T-cell 
memory inflation that is sustained over time.
Similar to CD8+ T cells, inflated memory CD4+ T cells 
have a phenotype of CD45RA− TEM, and RA
+ revertants that 
lack CD27−CD28−PD-1− cell markers are also positive for 
CX3CR1+ [48]. In the current study, we show that in a subset 
of PLWH, CMV-specific CD45RA−CD4+ inflated TEM cells 
occur in HIV/CMV-coinfected individuals who have sus-
tained viral suppression on ART. Similar to the findings of 
Abana et  al [48] and Pachnio et  al [50], we found that the 
CD27−CD28+ TEM cells expand at the highest frequency in 
response to CMV, and these are CX3CR1+CD4+ T cells [48, 
50]. Of interest, the CMVpp65-specific TEM cell frequency in 
our study, which ranged from 0% to 60%, was lower than that 
found by Abana et  al [48] using tetramer specific for glyco-
protein B.  This difference is largely due to the difference in 
response to the CMVpp65 peptide pool used in our studies, 
which unlike glycoprotein B, tends to elicit less memory infla-
tion. Our findings that CD4+ T-cell inflation was CMV specific 
and not due to a bystander effect of inflammation or the pres-
ence of another herpesvirus (EBV) further supports the idea 
that these findings are CMV specific. CMV-directed inflated 
CD4+ T cells are proatherogenic, producing IFN-γ and TNF-α 
(discriminating them from exhausted T cells), and expressing 
CX3CR1, perforin, and granzyme [48, 51].
In conclusion, HIV/CMV-coinfected individuals maintain 
their CMV response state independent of the level of CMV DNA 
present in PBMCs. Individuals with high CMV frequencies 
harbor high frequencies of CD4+CX3CR1+ T cells that are as-
sociated with CVD, which probably places these IFN-γ HRs 
at increased risk for CVD and other CMV-associated inflam-
matory conditions. Drugs designed to interrupt the CX3CR1-
CX3CL1 interaction may prove beneficial in decreasing the 
effects of chronic inflammation associated with CMV and other 
drivers of inflammation associated with CVD.
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